Abstract
The U.S. Food and Drug Administration approval of dupilumab for moderate-to-severe atopic dermatitis shifted the paradigm from use of broad, systemic immunosuppressants to a safer, targeted treatment and led to the emergence of newer interleukin (IL)-4/IL-13 directed biologics and small molecule therapies, namely Janus kinase (JAK) inhibitors (JAKi). Tralokinumab and emerging (not yet approved) lebrikizumab, which both target IL-13, are alternative biologics to dupilumab. The emerging anti–IL-31 receptor nemolizumab is likely to be used second-line to other biologics, primarily for pruritus. Three JAKi are currently in use for treating atopic dermatitis, 2 of which, abrocitinib and upadacitinib, are U.S. Food and Drug Administration–approved. This review provides an in-depth, practical discussion on use of these biologics and JAKi that are approved or have completed phase 3 clinical trials in pediatric patients and adults, comparing the groups of medications based on available efficacy and safety data.
Original language | English (US) |
---|---|
Pages (from-to) | 1361-1373 |
Number of pages | 13 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 11 |
Issue number | 5 |
DOIs | |
State | Published - May 2023 |
Keywords
- Abrocitinib
- Atopic dermatitis
- Baricitinib
- Biologics
- Cytokine signaling
- Dupilumab
- Eczema
- Interleukin-13
- Interleukin-4
- Janus kinase itnhibitor
- Lebrikizumab
- Nemolizumab
- Tralokinumab
- Upadacitinib
ASJC Scopus subject areas
- Immunology and Allergy